Lost Women of Science

“The only time I ever saw something that I thought was abnormal…there was a human arm in the refrigerator,” said J. Peter Willard about his aunt, Mary Louisa Willard. Otherwise, he insisted, she was “very normal.” But Mary Louisa Willard, a chemistry professor at Pennsylvania State University in the late 1920s, left a strong impression on most people, to say the least. Her hometown of State College, Pennsylvania, knew her for stopping traffic in her pink Cadillac to chat with friends, and for throwing birthday bashes for her beloved cocker spaniels. Police around the world knew her for her side hustle: using chemistry to help solve crimes. Learn about your ad choices: dovetail.prx.org/ad-choices

“La única vez que vi algo que me pareció anormal… había un brazo humano en el refrigerador”, dijo J. Peter Willard sobre su tía, Mary Louisa Willard. Por lo demás, insistió, era “muy normal.” Pero Mary Louisa Willard, profesora de química en la Universidad Estatal de Pensilvania a finales de la década de 1920, dejó una fuerte impresión en la mayoría de las personas. Su ciudad natal, State College (Pensilvania), la conocía por detener el tráfico en su Cadillac rosa para saludar a sus amistades, y por organizar fiestas de cumpleaños para sus queridos perritos cocker spaniels. La policía la conocía por su oficio secundario: usar la química para resolver crímenes. Learn about your ad choices: dovetail.prx.org/ad-choices

Elizabeth Roboz Einstein’s life was shaped by the forces of history. She studied bioorganic chemistry at the University of Vienna in the 1920s and then left her home country of Hungary during World War II, before German troops invaded — practically a miracle for a single, Jewish woman. In the U.S., she blazed a trail in the brand new field of neurochemistry; her seminal research into multiple sclerosis (MS) unlocked key findings that would make effective medical treatments for MS possible. Learn about your ad choices: dovetail.prx.org/ad-choices

In this episode of Lost Women of Science Conversations, host Carol Sutton Lewis speaks with science writer Hanne Strager about her biography of Inge Lehmann, the pioneering Danish seismologist who discovered that Earth has a solid inner core.. Largely unknown outside scientific circles, Lehmann fundamentally transformed our understanding of what lies at the heart of our planet. She did this in 1936 by identifying anomalies in earthquake waves that others had overlooked. At the time, scientists believed Earth’s core was entirely liquid. Lehmann proposed instead that a solid inner core lay hidden within it — a groundbreaking insight that reshaped geophysics. In revisiting Lehmann’s story, Strager highlights that Lehmann’s legacy is one of resilience and perseverance — proof that early setbacks do not define a life, and that brilliance can flourish, even later in life. Learn about your ad choices: dovetail.prx.org/ad-choices

This bonus episode is a co-production with Distillations, a podcast produced by the Science History Institute. Agnes Pockels did pioneering work in surface science. Her invention, the Pockels Trough, became the basis for an instrument that helped Katherine Burr Blodgett and Irving Langmuir make discoveries in material science that quietly shape our everyday world. But the way we talk about Agnes’s life and work often falls back on familiar tropes about women’s domestic roles, assumptions about how science gets done, and what it looked like to do science as a woman in the 19th century. Agnes's story invites us to rethink how we define success for scientists. Is our definition too narrow? And what might we gain if we crack it open a bit wider? Learn about your ad choices: dovetail.prx.org/ad-choices

How is a legacy preserved, and how is someone forgotten? Determined to make a final name for himself, Irving Langmuir ventures into science that even he might classify as pathological wishful thinking, while Katharine continues her work as the diligent experimenter. But her contributions faded from both the company’s and the public’s memory. We go to visit her, to say good-bye – and we look at the wisdom she imparted to the next generation of ​​inquiring minds. Learn about your ad choices: dovetail.prx.org/ad-choices

Katharine’s relatives lead the production team to a collection of papers and artifacts stored in a New England storage unit, revealing an inner struggle she kept carefully out of sight – even as she was making history in the laboratory. Learn about your ad choices: dovetail.prx.org/ad-choices

The 1930s prove to be an exceptional decade for research at The General Electric Company. Katharine Burr Blodgett works closely alongside her boss, Irving Langmuir who, in 1932, wins the Nobel Prize for Chemistry. In 1938, Katharine’s meticulous experiments with thin film coatings on solid surfaces lead to her most important breakthrough: non-reflecting glass. The General Electric Company’s public relations machine kicks into high gear. Katharine becomes an overnight sensation, both in the scientific community and in the press, which dub her discovery “invisible glass.” The assistant to the Nobel Prize winner, long invisible herself, takes center stage. Learn about your ad choices: dovetail.prx.org/ad-choices

The only woman in a laboratory filled with men, Katharine Burr Blodgett soon becomes indispensable as an assistant to The General Electric Company’s most famous scientist, Irving Langmuir. Their working relationship is an elegant symbiosis: her forte is experimentation, his is scientific theory. We follow their partnership as they successfully find ways to build a better lightbulb but Langmuir stumbles with an off-the-wall theory of matter. All the while, Katharine builds her life in Schenectady: going to church, making new friends, falling in love. In 1924, she embarks on a new journey to the University of Cambridge, where she studies with some of the most prominent physicists of the 20th century. Learn about your ad choices: dovetail.prx.org/ad-choices

Katharine Burr Blodgett arrives at The General Electric Company’s legendary research laboratory in Schenectady, New York, known as the “House of Magic.” She was just 20 years old when she entered a world built almost entirely for men. She joins as assistant to the brilliant and eccentric Irving Langmuir, a star chemist whose fundamental work in materials science and light bulbs would bring fame to him, and fortune to GE. The General Electric Company was an obvious choice for a brilliant young scientist. But was it the promise of scientific discoveries that drew Katharine to Schenectady or the need to confront the personal tragedy that marked the place where her own story began? Perhaps it was both. Learn about your ad choices: dovetail.prx.org/ad-choices

In the first of this five-part season we trace Katharine’s early years as she picks up European languages, her early scientific education at a progressive New York school for girls and then Bryn Mawr, a women’s college. She seems destined to end up working at the General Electric Company’s industrial research lab, but first she must prove herself at the University of Chicago, where, in the middle of World War I, she works to improve the life-saving gas mask. Learn about your ad choices: dovetail.prx.org/ad-choices

Introducing Layers of Brilliance, a five-part season that brings to life the story of a woman whose discoveries in materials science quietly shape our everyday world – but whose legacy was long eclipsed by the famous scientist she worked with. In 1918, at just twenty years old, Katharine Burr Blodgett arrived at the General Electric Company’s industrial research laboratory in Schenectady, New York – a place known as the House of Magic. There she began a decades-long collaboration with Irving Langmuir, GE’s star scientist, who would go on to win the Nobel Prize in Chemistry. While Langmuir became a public figure, Blodgett became something else: the mind and hands behind experiments so delicate they operated at the scale of single molecules. Blodgett’s work on films just one molecule thick would lead to multiple U.S. patents and form the basis of technologies embedded in today’s screens, optics, and electronics. Listen as we peel back the layers of Katharine Burr Blodgett’s life – how she made groundbreaking science inside a world built for men, how she struggled against profound personal challenges, and how a woman whose work helped shape modern materials science nearly disappeared from history. Learn about your ad choices: dovetail.prx.org/ad-choices

The Lost Women of Science by Melina Gerosa Bellows and Katie Hafner is an exciting book for young readers that brings to life the stories of ten remarkable women who changed the world of science but have been forgotten, or written out of history completely. Published by Penguin Random House’s Bright Matter imprint, the book transforms podcast episodes into a collection of inspiring biographies written for middle school readers. In this Lost Women of Science Conversation, Melina and Katie talk about their favorite female scientists and why their grit and determination can help inspire curiosity in the next generation of young female (and male) scientists. For parents, teachers or grandparents looking to spark a love of science in the young people in their lives, look no further than this book this holiday season. Learn about your ad choices: dovetail.prx.org/ad-choices

In 2022, Susan Wojcicki was on top of the world—CEO of YouTube, parent to five kids, and running a few miles a day—when she received a shocking diagnosis: metastatic lung cancer. She soon resigned from YouTube and dedicated herself to fighting the disease and looking for answers. Why does the leading cause of cancer deaths receive less funding than some less lethal cancers? How could her lung cancer have progressed so far undetected? And how did Susan get lung cancer, when she had never smoked? This episode is dedicated to her. Learn about your ad choices: dovetail.prx.org/ad-choices

In the 1910s, a relatively unknown cancer researcher named Maud Slye announced the first results of a study with the loftiest ambitions: to identify what causes cancer. To answer that question, the University of Chicago geneticist had bred tens of thousands of mice, enough to fill a three-story building. She carefully documented their ancestry and their morbidities and performed autopsies. And to Slye, her findings were clear: vulnerability to cancer was hereditary. If we wanted to, we could eliminate it. But Slye made some crucial mistakes along the way—and a number of enemies. Learn about your ad choices: dovetail.prx.org/ad-choices

Composer Peter Hugh White and librettist Clare Heath join host Rosie Millard in front of a London audience to explore why the story of chemist and x-ray crystallographer Rosalind Franklin and the race to uncover the structure of DNA makes such a compelling subject for an opera. We hear excerpts that capture the contrasting personalities at the centre of this scientific drama — James Watson, the brash young researcher at the University of Cambridge; Francis Crick, his more measured collaborator; and Maurice Wilkins, an anxious biophysicist uneasy about being outshone by his brilliant colleague, Franklin. It’s a story of ambition, rivalry, and betrayal: Franklin’s departure from King’s College London and the subsequent publication of the double helix model by Watson and Crick, which was built on insights from her work — yet without giving her due recognition. Learn about your ad choices: dovetail.prx.org/ad-choices

Although initial clinical trials of tamoxifen as a treatment of breast cancer were positive, Imperial Chemical Industries (ICI) did not believe this market would be commercially viable. The company had hoped for a contraceptive pill – tamoxifen didn’t work for that – not a cancer treatment. In 1972 the higher-ups at ICI decided to cancel the research.‍ But Dora Richardson, the chemist who had originally synthesized the compound, and her boss, Arthur Walpole, were convinced they were on to something important, something that could save lives. They continued the research in secret. Tamoxifen was eventually launched in 1973 and went on to become a global success, saving hundreds of thousands of lives. Dora Richardson’s role in its development, however, was overshadowed by her a male colleague and all but forgotten. This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez. Learn about your ad choices: dovetail.prx.org/ad-choices

Aunque los ensayos clínicos iniciales del tamoxifeno como tratamiento del cáncer de mama fueron positivos, Imperial Chemical Industries (ICI) no creía que este mercado fuera comercialmente viable. La compañía esperaba una píldora anticonceptiva (el tamoxifeno no funcionó para eso), no un tratamiento contra el cáncer. En 1972, los superiores del ICI decidieron cancelar la investigación. ‍ Pero Dora Richardson, la química que originalmente había sintetizado el compuesto, y su jefe, Arthur Walpole, estaban convencidos de que estaban en algo importante, algo que podría salvar vidas. Continuaron la investigación en secreto. El tamoxifeno se lanzó finalmente en 1973 y se convirtió en un éxito mundial, salvando cientos de miles de vidas. El papel de Dora Richardson en su desarrollo, sin embargo, fue eclipsado por su colega masculino y casi olvidado. Learn about your ad choices: dovetail.prx.org/ad-choices

In the early 1960s, Dr. Dora Richardson synthesized a chemical compound that became one of the most important drugs to treat breast cancer: tamoxifen. Although her name is on the original patent, her contributions have been lost to history. In the first episode of this two-part podcast, Katie Couric introduces us to Dora’s story, and we show how Lost Women of Science producer Marcy Thompson tracked down Dora’s firsthand account of the history of the drug’s development. This document, lost for decades, tells the story of how the compound was made and how Imperial Chemical Industries, where Richardson worked, almost terminated the project because the company was hoping to produce a contraceptive, not a cancer therapy. This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez. Learn about your ad choices: dovetail.prx.org/ad-choices

A principios de la década de los sesenta, la Dra. Dora Richardson sintetizó un compuesto químico que se convirtió en uno de los medicamentos más importantes para tratar el cáncer de mama: el tamoxifeno. Aunque su nombre aparece en la patente original, sus contribuciones fueron olvidadas por la historia. En el primer episodio de este podcast de dos partes, les contamos la historia de Dora y de cómo Marcy Thompson, productora de Lost Women of Science, rastreó su relato en primera persona sobre el desarrollo del medicamento. Este documento, perdido durante décadas, narra cómo se creó el compuesto y cómo la empresa Imperial Chemical Industries, donde trabajaba Richardson, estuvo a punto de cancelar el proyecto porque buscaba desarrollar un anticonceptivo, no una terapia contra el cáncer. Learn about your ad choices: dovetail.prx.org/ad-choices